Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Discodermolide is a polyketide natural product originally isolated from the marine sponge *Discodermia dissoluta*. It is a highly potent microtubule-stabilizing agent that promotes tubulin polymerization and assembly, leading to G2/M phase cell cycle arrest and apoptosis in tumor cells. Discodermolide is effective against multidrug-resistant cancer cell lines and demonstrates immunosuppressive as well as neuroprotective properties. The compound induces accelerated cellular senescence and exhibits synergistic antiproliferative effects in combination with paclitaxel. It was licensed for drug development and entered early-phase clinical trials as a potential antineoplastic agent. Owing to its scarcity in nature, discodermolide used in studies has been produced via total synthesis[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on discodermolide.